LAUSR

Key Points Question What are the comparative short-term and long-term outcomes associated with first-line chemotherapy regimens for patients with metastatic pancreatic cancer, and how do they compare with chemotherapy regimens recommended in Japanese guidelines? Findings In this systematic review and network meta-analysis of 25 randomized clinical trials assessing first-line chemotherapy regimens for advanced or metastatic pancreatic cancer, results were consistent with and complementary to the Japanese guidelines for pancreatic cancer treatment. Oxaliplatin, irinotecan, fluorouracil, and leucovorin combination (FOLFIRINOX) and gemcitabine plus albumin-bound paclitaxel (GEM+NPTX) had better outcomes associated with reduced risk of death as primary chemotherapy for pancreatic cancer than the unapproved drugs in Japan. Meaning In this network meta-analysis, a similar trend in the curve estimation was found in randomized clinical trials, indicating that the values are consistent between the short and long terms; results suggest that FOLFIRINOX and GEM+NPTX can be regarded as regimens with the best outcomes compared with regimens not approved in Japan.